Bayer's Two-Pronged Reset: A €2 Billion Bond, a $7.25 Billion Roundup Deal, and a Stock That Has Climbed 36% This Year
Published on 09/27/2026 at 16:20 | Editorial boerse-global.de
Bayer shares finished Friday's session in Frankfurt at €50.20, a gain of 1.3% on the day and a rise of 36% since the start of the year. The advance reflects a company that is simultaneously cleaning up its portfolio, rebuilding its capital structure, and waiting on a single US courtroom decision that could define its next chapter.
At the center of investor attention sits the long-running glyphosate saga. Monsanto has asked a judge in Missouri to approve a $7.25 billion settlement covering nearly all existing and future US cancer claims tied to Roundup. According to Reuters, that settlement remains the single largest burden weighing on Bayer. A judge's sign-off would put a firm ceiling on liabilities that have, until now, been impossible to quantify across thousands of individual lawsuits.
The stock has added 3.0% since the hearing on the consolidated Roundup settlement took place roughly two weeks ago. Until a final ruling lands, legal risk continues to dominate how the market values the Leverkusen-based agricultural and pharmaceutical group. Management needs financial predictability to fully reopen strategic room in its business units, which is why every procedural signal out of US courtrooms moves the risk-reward profile of the equity.
Analysts Position Themselves for a Legal Breakthrough
Sell-side sentiment has tilted cautiously constructive. Barclays raised its price target to €70.00 on September 8 while keeping a positive rating, implying meaningful upside if the legal knot finally loosens. Deutsche Bank, per media reports, reaffirmed its €60.00 target on September 10, and other institutional houses published targets above the current quote in early September.
How quickly the remaining legal uncertainty clears will determine how much of that potential re-rating actually materializes. While the US approval is pending, the market continues to price in caution. A durable end to the litigation, by contrast, could open the door to a fresh assessment of the company's worth.
Should investors sell immediately? Or is it worth buying Bayer?
Portfolio Trimming Runs in Parallel
Bayer is not waiting on the courts to act. The group has agreed to sell its cancer drug Stivarga to Aachen-based Grünenthal for up to €375 million. The transaction is subject to customary closing conditions and regulatory clearances, with both sides expecting completion around the end of 2026 or the start of 2027.
On the financing side, Bayer issued hybrid bonds totaling €2 billion, split into two tranches of €1 billion each. The notes carry 30-year maturities and coupons of 5.75% and 6.25%. The placement lifted the group's total outstanding hybrid bond volume to €6.55 billion, with proceeds earmarked for general corporate purposes.
Ownership also shifted. Asset manager Amundi disclosed in a voting rights notification that it had crossed the statutory reporting threshold and now holds 3.04% of Bayer's voting rights.
Pipeline and Consumer Health Add Fresh Impulses
Operationally, Bayer continues to push its core franchises forward. The company described finerenone as the first newly approved treatment option for this patient group in more than 30 years. Through its Leaps by Bayer unit, the group led a Series A financing round in Robigo, tying the startup's biological crop protection solutions into its own portfolio.
In Consumer Health, Bayer introduced a recyclable mono-material package for Talcid in Germany on Wednesday, with a phased rollout across eleven additional European countries planned through 2027.
Trading in recent sessions has come without fresh company-specific catalysts, leaving market watchers to focus on the step-by-step execution of management's strategic targets: streamlining the product range, investing in promising technologies, and shoring up existing liabilities. The longer-term chart reflects that steady progress — the stock currently trades 17% above its 200-day moving average. For investors, the key question remains how far the portfolio adjustments can go in further relieving pressure on the balance sheet.
Ad
Bayer Stock: New Analysis - 27 September
Fresh Bayer information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
